Personalized or targeted medicine is transforming how we treat conditions like obesity. Our Board-Certified gastroenterologist at Atlantic Gastroenterology, Dr. Alexander Shapsis, stays on top of the latest research to benefit patients with persistent weight loss challenges in Brooklyn and greater New York City. Notably, research partly supported by the Mayo Clinic and featured in the April 2021 issue of the journal Obesity suggests strides in:
Eighty-five percent of the initial 450 study participants were classified into “subgroups” and subject to phenotype-based treatment. Individuals were classified into these subtypes or phenotypes based on available tests to assess and measure functions like gastric emptying and metabolism, as well as questionnaires completed by participants. From there, the year-long study categorized participants into one of the four following phenotypes:
From here, medications were prescribed to each participant based on the identified phenotype. The optimal medication for each phenotype was derived from the primary mechanism of action and previous studies exploring how subgroups responded to these drugs. The medications that were selected to treat each phenotype in this study are as follows:
Researchers found that 79% of those subjects within the phenotype-based treatment group lost at least 10% of their weight at the 12-month mark. For comparison, 34% of those treated with a “non-phenotype-based” approach lost 10-plus% of their weight after one year. The mean weight loss for the former, phenotype-based group was nearly 16% (versus 9% for the latter, non-phenotype group). In all, such a subtype-based approach to treatment was associated with 1.75-fold greater weight loss than those medications and treatments that were not driven by these individuals’ identified phenotypes.
Historically, weight loss interventions have been limited. They did not account for nuances and dissimilarities among obese individuals. Based on their findings, researchers have concluded that phenotype groups are “clinically meaningful.” Validated by biological and behavioral analyses, this research reportedly supports an enhanced understanding of pathophysiology within each subgroup. In turn, tailored, phenotype-based pharmacotherapy demonstrated greater weight loss. These findings may be used to advance precision medicine approaches designed to successfully treat obesity.
Benefit from tomorrow’s therapies and interventions today. Contact our state-of-the-art specialty team at Atlantic Gastroenterology. Our offices in Brooklyn, NY, may be reached at 718 521-2840.
Weight loss medications like Ozempic can be effective tools for individuals struggling to lose weight,…
At EndoSlim Clinic NY of Atlantic Gastroenterology, Dr. Alexander Shapsis, our Board-certified gastroenterologist and obesity…
With obesity rates soaring, the United States grapples with a concern that extends far beyond…
The Spatz3 Adjustable Gastric Balloon is a cutting-edge medical device designed for weight loss management.…
Ozempic is one of several medications on the medical market today approved by the FDA…
Bariatric procedure, both surgical and endoscopic, is a life-changing step for those struggling with severe…